Affiliation:
1. Bryansk Regional Hospital No. 1; Kursk State Medical University
2. Kursk State Medical University
3. Mandryka Central Clinical Hospital; Pirogov Russian National Research Medical University
4. Treatment and Diagnostic Center No. 9
Abstract
Studies in recent years have shown an increase in the prevalence of systemic diseases, some of which may be independent risk factors for the development and progression of glaucoma. Metabolic syndrome (MetS) is currently one of the leading public health problems in the world. Some studies indicate a relationship between MetS and its individual components (in particular, insulin resistance, hyperglycemia, impaired homeostasis, and systemic arterial hypertension) with an increase in intraocular pressure (IOP), ocular hypertension, and the development of primary open-angle glaucoma (POAG). However, no unambiguous conclusions about the role of MetS in the pathogenesis of glaucoma has been established due to the insufficient number of scientific studies on this topic, the differences in their methodology, and the contradictory results. Further research is needed to determine the role and place of MetS in the occurrence and development of POAG, and the prospects for the practical application of this knowledge.This review presents literature data on the effect of MetS and its individual components on IOP, occurrence and development of glaucoma and several other ophthalmic diseases
Publisher
Research Institute of Eye Diseases
Reference79 articles.
1. Uspenskiy Y.P., Petrenko Y.V., Gulunov Z.K. et al. Metabolicheskii sindrom. Uchebnoe posobie [Metabolic syndrome. Manual]. Saint Petersburg, 2017. 60 p.
2. Oganov R.G., Simanenkov V.I., Bakulin I.G. et. al Comorbidities in clinical practice. Algorithms for diagnostics and treatment. Cardiovascular Therapy and Prevention 2019; 18(1):5-66. https://doi.org/10.15829/1728-8800-2019-1-5-66
3. Uspenskiy Y.P., Sousova Y.V., Gulunov Z.K. et al. Actual problems of metabolic syndrome and associated clinical conditions. Diary of the Kazan Medical School 2018; 3(21):182-187.
4. Fominykh Y.A., Uspenskiy Y.P., Sousova I.V., Gulunov Z.K. Comboridity in metabolic syndrome: solved and unsolved issues. University therapeutic journal 2020; 1(1):84-101.
5. Stein J.D., Newman-Casey P.A., Niziol L.M. et al. Association Between the Use of Glaucoma Medications and Mortality. Arch Ophthalmol 2010; 128(2):235-240. https://doi.org/10.1001/archophthalmol.2009.378.